- Previous Close
9.50 - Open
9.50 - Bid 9.25 x --
- Ask 9.42 x --
- Day's Range
9.20 - 9.55 - 52 Week Range
8.38 - 20.45 - Volume
15,426 - Avg. Volume
35,327 - Market Cap (intraday)
149.501M - Beta (5Y Monthly) 0.55
- PE Ratio (TTM)
14.68 - EPS (TTM)
0.63 - Earnings Date Apr 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.17
Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. Mabion S.A. was founded in 2007 and is based in Konstantynów Lódzki, Poland.
www.mabion.euRecent News: MAB.WA
View MorePerformance Overview: MAB.WA
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MAB.WA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MAB.WA
View MoreValuation Measures
Market Cap
153.54M
Enterprise Value
110.23M
Trailing P/E
15.08
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.39
Price/Book (mrq)
1.19
Enterprise Value/Revenue
0.99
Enterprise Value/EBITDA
3.64
Financial Highlights
Profitability and Income Statement
Profit Margin
9.24%
Return on Assets (ttm)
9.56%
Return on Equity (ttm)
8.24%
Revenue (ttm)
110.79M
Net Income Avi to Common (ttm)
10.24M
Diluted EPS (ttm)
0.63
Balance Sheet and Cash Flow
Total Cash (mrq)
47.05M
Total Debt/Equity (mrq)
2.89%
Levered Free Cash Flow (ttm)
23.89M